Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Time Perspective : Most patients are expected to be a mix of retrospective and prospective
data collection. Patients can be enrolled after their study index date (retrospective
component) and have to be followed until 5 years from study index date are complete (time
between enrollment and 5 year follow-up is the prospective component)

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Newly-diagnosed chronic phase chronic myeloid leukemia (CP-CML) patients who started
their first-line Tyrosine Kinase Inhibitor (TKI) treatment on imatinib, dasatinib or
nilotinib in accordance with the timelines below

- 18 years or older at time of of CP-CML diagnosis

a) Imatinib Cohorts

- Patients who started their first-line Imatinib treatment between January 2, 2008 and
September 30, 2010.Patients fitting this criterion are defined as retrospective
Imatinib patients

− Patients who started their first-line Imatinib treatment on or after October 1, 2010

b) Dasatinib Cohort

- Patients who started their first-line Dasatinib treatment after the drug was approved
in this indication

c) Nilotinib Cohort

- Patients who started their first-line Nilotinib treatment after the drug was approved
in this indication

- Patients are also eligible when they have already switched to a subsequent therapy
(TKI or other) at the time of enrollment, as long as their first-line and subsequent
CML treatment information is available at site for data entry into the study
Electronic Case Report Form (eCRF)

- Receiving treatment at medical practice (eg. community-based, office-based,
hospital-based, academic setting, oncology center)

Exclusion Criteria:

- Patients who are participating in an interventional trial which may influence the
management of their CML disease will be excluded

Discontinuation Criteria:

- Enrolled patients who join an interventional trial which may influence the management
of their CML disease will be excluded at the time of entry into the interventional
trial